The effect of Cyclosporine in prognosis and clinical improvement in patients with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19 disease.; COVID-19; U07.1

• Registration Number: IRCT20200426047206N3
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Positive PCR test
Age between 18-60 years
patient with acute respiratory infectious symptoms and lung involvement
non-intubated patients

Exclusion Criteria

Allergy to Cyclosporin
Not willing to participate
Patients with cancer
Under treatment with immunosuppressor drugs
Pregnancy or breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change oxygenation. Timepoint: Daily for two weeks. Method of measurement: pulse oximeter.;Creatinine clearance status. Timepoint: Days 2, 4 and 6. Method of measurement: laboratory exam.;Inflammatory factors. Timepoint: Days 1 and 7. Method of measurement: Flow Cytometry.;Number of days hospitalized in the ward. Timepoint: Seventh day onward. Method of measurement: day.;Serum D.dimer. Timepoint: Days 1,3 and 7. Method of measurement: Enzymes.;Serum ferritin level. Timepoint: Days 1,3 and 7. Method of measurement: laboratory test.;TCD4+, TCD8+, B Cell. Timepoint: Days 1 and 7. Method of measurement: Flow Cytometry.;CRP. Timepoint: Days 1 and 7. Method of measurement: mg/L.